IMU Biosciences has extended its Series A to over $53 million in an oversubscribed round co-led by IQ Capital and Molten Ventures, with support from the British Business Bank and Meltwind alongside existing investors.
The London-based company has built the world’s largest immune dataset, covering more than 25,000 individuals and over 100 million immune data points measurable from a single blood sample.
Buildings account for roughly 39% of global carbon emissions — and in precision medicine, the immune system may be the equivalent missing variable: present in every major disease, yet still poorly mapped at clinical scale.
Doctors can sequence your entire genome. They still cannot fully read your immune system, the biological layer that determines whether a cancer treatment works, whether a transplanted organ survives, or whether the body attacks itself. IMU Biosciences just raised $53 million to change that.
The London-based biotechnology company has announced an oversubscribed extension to its Series A, bringing total Series A funding to more than $53 million. The round was co-led by IQ Capital and Molten Ventures, with participation from the British Business Bank and Meltwind alongside existing investors. Molten Ventures is IMU’s largest shareholder.
